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Abstract
Background: Few studies have addressed whether the combined use of B-type natriuretic peptide (BNP)
and high-sensitive C-reactive protein (hsCRP) improves risk stratification for mortality and cardiovascular
events in a population with chest pain and suspected acute coronary syndromes (ACS). Therefore, we
wanted to assess the incremental prognostic value of these biomarkers with respect to long-term all-cause
mortality and recurrent troponin T (TnT) positive cardiac events in 871 patients admitted to the
emergency department.
Methods: Blood samples were obtained immediately following admission.
Results: After a follow-up period of 24 months, 129 patients had died. The BNP levels were significantly
higher among patients dying than in long-term survivors (401 (145–736) versus 75 (29–235) pq/mL
[median, 25 and 75% percentiles], p = 0.000). In a multivariable Cox regression model for death within 2
years, the hazard ratio (HR) for BNP in the highest quartile (Q4) was 5.13 (95% confidence interval (CI),
1.97–13.38) compared to the lowest quartile (Q1) and was associated with all-cause mortality above and
beyond age, congestive heart failure and the index diagnosis ST-segment elevation myocardial infarction.
HsCRP rendered no prognostic information for all-cause mortality. However, within 30 days, the adjusted
HR for patients with recurrent TnT cardiac positive events hsCRP in Q4 was 14.79 (95% CI, 1.89–115.63)
compared with Q1 and was associated with recurrent ischemic events above and beyond age,
hypercholesterolemia and TnT values at admission.
Conclusion: BNP may act as a clinically useful biomarker when obtained at admission in an unselected
patient population following hospitalization with chest pain and potential ACS, and may provide
complementary prognostic information to established risk determinants at long-term follow-up. Our data
do not support the hypothesis that the additional assessment of hsCRP will lead to better risk stratification
for survival than BNP alone.
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Background
B-type natriuretic peptide (BNP) is a counter-regulatory
peptide hormone predominantly synthesized in the ven-
tricular myocardium. BNP is released into the circulation
in response to ventricular dilatation and pressure over-
load, and reflects ventricular wall stress and tissue hypoxia
rather than cell injury per se [1,2]. It is a well known
marker of left ventricular dysfunction and heart failure
(HF), and it provides prognostic information beyond and
above left ventricular ejection fraction (LVEF) in patients
with acute coronary syndromes (ACS) [3]. This marker of
neurohormonal activation plays a pivotal role across the
spectrum of ACS, including patients with ST-elevation
myocardial infarction (STEMI) and non ST-elevation
myocardial infarction (NSTEMI). Moreover, elevated
natriuretic peptides at presentation have been shown to
identify patients with ACS who are at higher risk of death
and HF and add information to that provided by the tro-
ponins [4-6].
C-reactive protein (CRP) is an acute-phase reactant that is
produced in response to acute injury, infection or other
inflammation stimuli. It is a marker for underlying sys-
temic inflammation, and it has been suggested to play a
role in the initiation and propagation of atherosclerosis
and ultimately to plaque rupture and the ensuing throm-
botic complication [7]. Elevated levels of CRP were first
reported in patients hospitalized with ACS in the early
1990s and were shown to predict mortality [8,9]. Through
the use of appropriate high-sensitive assays, it has been
possible to investigate the relationship between plasma
CRP levels that previously were considered to be normal
and cardiovascular disease (CVD).
Nevertheless, it is still under debate which markers should
be preferred for risk prediction [10,11]. It has been sug-
gested that the combined evaluation of natriuretic pep-
tides and CRP may yield incremental prognostic
information in the risk stratification of patients with ACS
[12,13], and their combined use has been shown to
improve long-term risk prediction of mortality in patients
with stable coronary heart disease (CHD) [14]. To our
knowledge, there are limited data available that directly
compare these two markers in a prospective manner in an
unselected patient population presenting to the emer-
gency department (ED) with chest pain. In addition, their
role in risk stratification in patients with ACS is still under
evaluation, and therefore additional investigations are
necessary.
The aims of this study were to explore the ability of BNP
and hsCRP to predict risk of death and recurrent troponin
T (TnT) positive cardiac events within 24 months in a
patient population hospitalized with chest pain and sus-
pected ACS, and to evaluate the incremental prognostic
value of these biomarkers for risk stratification in ACS.
Methods
Study Design and Patient Population
The study was a single-center prospective follow-up study
(RACS: Risk in the Acute Coronary Syndrome) in which
871 patients with chest pain and potential ACS were con-
secutively admitted to the ED of Stavanger University
Hospital, Stavanger, Norway from November 2002 to
September 2003. The main exclusion criteria were age <
18 years or unwillingness or incapacity to provide
informed consent and prior inclusion in the present
study. Patients with missing data for BNP or hsCRP were
excluded from the present analyses.
The primary outcome measure of the present study was
all-cause mortality from the time of inclusion until 2 years
follow-up. The secondary outcome included the com-
bined endpoint of cardiac death or recurrent TnT positive
cardiac events (TnT > 0.05 ng/mL and a pattern of gradual
rise and fall in TnT) and a third endpoint consisted of
recurrent TnT positive cardiac events.
Survival status, date and cause of death and clinical data
were obtained by telephone interview at 30 days, 6, 12
and 24 months during the 2 year follow-up period. In case
of incapacity to provide information, the general practi-
tioner or nursery home were contacted to obtain relevant
data. In addition, hospital journals were searched for con-
firmation of reported data.
Clinical and laboratory parameters, including assessment
of previous MI, angina pectoris, CHF, diabetes mellitus
(defined as either whole blood fasting glucose concentra-
tions above 6.1 mmol/L, two hour post glucose load con-
centrations above 10.0 mmol/L or medical treated
diabetes mellitus), smoking status (stratified in categories
of current smokers, previous smokers or patients who
never smoked), hypercholesterolemia (defined as total
cholesterol concentrations above 6.5 mmol/L or medical
treated hypercholesterolemia) and arterial hypertension
(defined as repeated blood pressure measurements above
140/90 mmHg or treated hypertension) were based on
hospital records and personal interviews.
Electrocardiographic (ECG) findings at admission were
classified according to the presence of ST-segment changes
(i.e. ST-segment depression or elevation, T-wave inversion
or left bundle-branch block). The term ACS in the present
study encompasses unstable angina (UAP), NSTEMI and
STEMI. The following classification for the index diagno-
sis was used: STEMI; ST-segment elevation combined with
TnT values > 0.05 ng/mL. NSTEMI; Transient ST-segment
elevation, ST-segment depression, or T-wave inversion in
at least 2 contiguous leads combined with TnT values >
0.05 ng/mL. UAP; Transient ST-segment depression or T-
wave inversion and TnT values < 0.05 ng/mL. No-ACS; All
other conditions (i.e. unspecific chest pain, arrhythmias,BMC Cardiovascular Disorders 2008, 8:34 http://www.biomedcentral.com/1471-2261/8/34
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atrial fibrillation etc.) without ECG changes and with neg-
ative troponins.
Written informed consent was obtained from all patients
and the study was approved by the Regional Board of
Research Ethics and the Norwegian Health authorities and
conducted in accordance with the Helsinki declaration of
1971, as revised in 1983.
Blood Sampling Procedures and Laboratory 
Measurements
Peripheral blood samples for determination of TnT, s-cre-
atinine, s-glucose, s-lipids, hsCRP and BNP were drawn
immediately following admission by direct venipuncture
with a minimum of stasis of an antecubial vein. A
repeated blood sample for the determination of TnT was
drawn 7 hours following the primary blood sample. Clot-
ted whole blood and ethylene diamine tetraacetic acid
(EDTA) blood samples were centrifuged for 15 min with
2000 g and 20°C without delay. Serum for hsCRP and
EDTA plasma for BNP were immediately frozen and
stored at -80°C until the measurements were performed.
For all other biochemical parameters, measurements were
performed immediately following centrifugation.
BNP was analysed in EDTA plasma using the Microparti-
cle Enzyme Immunoassay (MEIA) Abbott AxSYM®
(Abbott Laboratories, Abbott Park, Illinois, USA). The
dynamic range was 0–4000 pg/mL and the within run
coefficient of variation (CV) was 6.3% at 95 pg/mL and
4.7% at 1587 pg/mL.
HsCRP was measured with the use of an immunoturbidi-
metric assay (Tina-quant® C-reactive protein (latex) high
sensitive assay, Roche Diagnostics, Germany) performed
on a Roche automated clinical chemistry analyzer (MOD-
ULAR P). The detection limit was 0.03 mg/L and the
measuring range 0.1–20.0 mg/L with an extended meas-
uring range with automatic re-run 0.1–300 mg/L. The
between-assay CV was 3.45% at 1.19 mg/L and 2.70% at
0.43 mg/L.
TnT was quantified by a cardiac-specific second-genera-
tion troponin T ELISA assay from Roche diagnostics, using
a high-affinity cardiac-specific TnT isoform antibody [15].
The lower detection limit of the assay used is 0.01 ng/mL.
In this study a cut off level of 0.05 ng/mL was used with a
CV of 10%.
Statistical Analysis
The patients were divided into quartiles on the basis of
their BNP and hsCRP levels. Approximately normally dis-
tributed variables were given as mean and standard devi-
ation (SD), while variables with more skewed
distributions were given as median and quartiles. The Chi-
square test for association was applied between the BNP
quartiles and categorical variables at baseline. The one-
way ANOVA test was used to test for equality of means of
scale variables (e.g. age), and the two-sample t test and
Mann Whitney test were used for comparing the means
and medians of two samples, respectively.
The hazard ratios (HR) are presented with 95% confi-
dence interval (CI). A stepwise Cox multivariable propor-
tional hazards regression model with total death, cardiac
death and TnT positive events as the dependent variable,
and BNP, hsCRP and other variables as potential inde-
pendent predictors (listed below) was fitted. To examine
the differences in prognosis between subjects in the upper
versus the lower quartile(s) of BNP, we adjusted for sex,
age, smoking, hypertension, index diagnosis, estimated
glomerular filtration rate, diabetes mellitus, HF, history of
previous CHD (i.e. history of either angina pectoris, MI,
coronary artery bypass grafting or percutaneous coronary
intervention), hypercholesterolemia, TnT > 0.05 ng/mL
and hsCRP dichotomized at a cut point of 10 mg/L at
admission and medication before enrollment (statins,
clopidogrel, beta-blockers, ACE inhibitors and angi-
otensin receptor blockers). The Kaplan-Meier product
limits were used for plotting the times to event.
In the discriminate analysis BNP, CRP, loge(BNP) and
loge(CRP) were used as individual variables. The statistical
analyses were performed using the statistical package SPSS
version 15.0. All tests were two-sided with a significance
level of 5%.
Results
A total of 871 patients were enrolled in the RACS study.
No BNP or hsCRP samples were available for 43 patients,
thus 828 patients were included in the present analysis.
No patient was lost to follow up. At index hospitalization,
367 patients (44.3%) had a peak TnT concentration
exceeding 0.05 ng/mL. Eleven patients (2.8%) of the total
population and 4 patients (3.2%) of the STEMI group pre-
sented with cardiogenic shock.
The baseline characteristics of the patients, stratified
according to BNP quartiles at admission are listed in Table
1. The median BNP concentration in plasma was 97.0
(33.3–310.8) pg/mL [25 and 75% percentiles]. Patients
with BNP in the higher quartiles were significantly older,
had higher concentration of TnT exceeding 0.05 ng/mL,
had diabetes mellitus, fewer were current smokers and
they had a higher percentage of a previous history of heart
failure, CVD and CHD. The time from symptom onset
until blood sampling was 12 (6–38) hours [median, 25
and 75% percentiles].
BNP, CRP, loge(BNP) and loge(CRP) were used in the dis-
criminate analysis as individual variables with the pur-
pose to identify patients with true ACS versus non-cardiacBMC Cardiovascular Disorders 2008, 8:34 http://www.biomedcentral.com/1471-2261/8/34
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chest pain and allocated 59.8%, 52.1%, 61.5% and
58.3%, respectively, of the observations correctly.
All-Cause Mortality
After a follow-up period of 24 months, 129 patients
(15.6%) had died. Kaplan-Meier survival curves for the
primary endpoint according to BNP and hsCRP quartiles
at baseline are presented in Figure 1. The BNP levels were
significantly higher among patients dying than in long-
term survivors (401 (145–736) versus 75 (29–235) pq/
mL [median, 25 and 75% percentiles], p = 0.000).
Receiver operated characteristics (ROC) curve for BNP is
shown in Figure 2; the area under the ROC for BNP was
0.778.
In a stepwise multivariable Cox regression model for
death within 30 days and 2 years, the HR's for patients
with BNP in the highest quartile (Q4) were 9.36 (95% CI,
1.10–79.83) and 5.13 (95% CI, 1.97–13.38), respectively,
compared with Q1 (Table 2 &3). Within 2 years the HR
was associated with all-cause mortality above and beyond
age, CHF and the index diagnosis of STEMI (Table 3). In
addition, in the subgroup composed of ACS patients, the
adjusted HR within 2 years for the primary endpoint in
Table 1: Baseline characteristics for patient strata according to quartiles of BNP
Quartiles of BNP, pg/mL
Characteristics < 33.0 33.0–96.0 > 96.0–310.0 > 310.0–4001.0 P value
Demographics
Age, y* 56.6 ± 13.4 67.8 ± 12.8 75.5 ± 10.7 78.4 ± 9.8 0.000
Female gender, % (n) 30.0 (62) 37.4 (77) 45.7 (95) 43.0 (89) 0.006
Risk markers at baseline
TnT > 0.05 (ng/mL), % (n) 34.8 (72) 41.7 (86) 42.3 (88) 58.5 (121) 0.000
hsCRP* (mg/L) 7.3 ± 16.7 11.2 ± 31.8 21.5 ± 60.0 32.0 ± 66.7 0.000
Risk factors
Hypercholesterolemia, % (n) 45.4 (94) 58.3 (120) 49.3 (102) 45.4 (94) 0.028
Total cholesterol (mmol/L)* 5.6 ± 1.2 5.2 ± 1.3 5.2 ± 1.3 4.9 ± 1.3 0.000
HDL cholesterol (mmol/L) * 1.3 ± 0.4 1.4 ± 0.5 1.4 ± 0.4 1.4 ± 0.5 0.305
Triglycerides (mmol/L) * 1.9 ± 1.6 1.6 ± 1.3 1.5 ± 0.9 1.4 ± 0.8 0.000
Current smoking, % (n) 41.5 (86) 25.2 (52) 19.2 (40) 19.3 (40) 0.000
Hypertension, % (n) 26.6 (55) 44.2 (91) 48.6 (101) 50.2 (104) 0.000
IDDM, % (n) 1.0 (2) 0.5 (1) 1.9 (4) 0.5 (1) 0.393
NIDDM, % (n) 5.8 (12) 14.1 (29) 14.4 (30) 15.5 (32) 0.010
eGFR* (ml/min/1.73 m2) 74.2 ± 17.6 66.3 ± 17.5 58.7 ± 20.3 50.9 ± 20.3 0.000
History of heart failure
CHF, % (n) 6.8 (14) 14.6 (30) 27.9 (58) 57.5 (119) 0.000
NYHA (I/II/III/IV), n 2/8/4/0 5/18/6/1 9/30/18/1 13/51/53/2 0.000
History of coronary heart disease
Angina pectoris, % (n) 30.9 (64) 42.7 (88) 48.1 (100) 52.7 (109) 0.000
MI, % (n) 15.0 (31) 30.1 (62) 38.5 (80) 48.3 (100) 0.000
CABG, % (n) 6.3(13) 12.1 (25) 9.6 (20) 12.6 (26) 0.128
PCI, % (n) 7.2 (15) 14.6 (30) 10.6 (22) 8.7 (18) 0.080
Treatment prior to admission
Statins, % (n) 26.1 (54) 41.3 (85) 34.6 (72) 34.8 (72) 0.014
Clopidogrel, % (n) 1.0 (2) 2.9 (6) 1.0 (2) 2.9 (6) 0.249
β-blocade, % (n) 16.4 (34) 38.3 (79) 42.8 (89) 45.9 (95) 0.000
ACE inhibitors, % (n) 10.6 (22) 16.0 (33) 21.2 (44) 27.1 (56) 0.000
ARB, % (n) 6.3 (13) 19.4 (40) 17.3 (36) 20.8 (43) 0.000
Diuretics, % (n) 12.1 (25) 20.4 (42) 36.5 (76) 55.1 (114) 0.000
Index diagnosis
STEMI, % (n) 18.4 (38) 18.4 (38) 11.1 (23) 11.6 (24) 0.042
NSTEMI, % (n) 15.9 (33) 23.8 (49) 31.3 (65) 46.9 (97) 0.000
UA, % (n) 2.4 (5) 4.9 (10) 13.9 (29) 15.5 (32) 0.000
No-ACS, % (n) 63.3 (131) 52.9 (109) 43.8 (91) 26.1 (54) 0.000
ACE; angiotensin converting enzyme, ARB; angiotensin receptor blockers, ACS; acute coronary syndrome, CABG; coronary artery bypass grafting, 
CHF; congestive heart failure, eGFR; estimated glomerular filtration rate, HDL; high-density lipoprotein, hsCRP; high-sensitive C-reactive protein, 
IDDM; insulin dependent diabetes mellitus, MI; myocardial infarction, NIDDM; non-insulin dependent diabetes mellitus, NYHA; New-York Heart 
Association functional class, STEMI; ST-segment elevation MI, NSTEMI; non ST-segment elevation MI, PCI; percutaneous coronary intervention, 
TnT; troponin T, UA; unstable angina pectoris. *Mean ± SDBMC Cardiovascular Disorders 2008, 8:34 http://www.biomedcentral.com/1471-2261/8/34
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Kaplan-Meier plots for the cumulative risk of the primary events (total mortality) for the BNP- and hsCRP quartiles, respec- tively Figure 1
Kaplan-Meier plots for the cumulative risk of the primary events (total mortality) for the BNP- and hsCRP 
quartiles, respectively. *Log Rank (Mantel-Cox) test of equality of survival distribution for the different levels of the BNP 
and hsCRP quartiles (univariate analysis).BMC Cardiovascular Disorders 2008, 8:34 http://www.biomedcentral.com/1471-2261/8/34
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Receiver operated characteristics curve for BNP Figure 2
Receiver operated characteristics curve for BNP.
BNP
PTX3
Table 2: Cox regression model for the total population showing association between selected baseline clinical variables and hazards 
ratios for the prespecified endpoints during 30 days follow-up
Variable Total Mortality* Cardiac Death or Recurrent TnT Positive 
Cardiac Events*
Recurrent TnT Positive Cardiac Events*
HR (95% CI) HR (95% CI) HR (95% CI)
BNP quartile 2 0.97 (0.09–11.07) 0.59 (0.20–1.74) 0.50 (0.15–1.74)
BNP quartile 3 3.49 (0.39–31.36) 1.63 (0.35–2.75) 0.52 (0.16–1.74)
BNP quartile 4 9.36 (1.10–79.83) 1.66 (0.60–4.55) 0.59 (0.18–1.97)
hsCRP quartile 2 0.25 (0.06–0.93) 1.01 (0.42–2.44) 9.94 (1.27–77.88)
hsCRP quartile 3 0.80 (0.31–2.02) 1.23 (0.53–2.88) 4.44 (0.51–38.57)
hsCRP quartile 4 0.71 (0.28–1.81) 1.55 (0.67–3.59) 14.79 (1.89–115.63)
Age 1.06 (1.01–1.11) 1.04 (1.01–1.07) 1.04 (1.00–1.08)
STEMI 0.19 (0.08–0.44) 0.41 (0.21–0.79)
ARB 2.84 (1.27–6.40)
TnT > 0.05 (ng/mL) 2.70 (1.06–6.84) 3.29 (1.62–6.65) 3.11 (1.41–6.88)
Hypertension 1.75 (1.01–3.03)
Hypercholesterolemia 2.22 (1.05–4.68)
ARB; Angiotensin receptor blockers, BNP; B-type natriuretic peptide, CI; Confidence interval, CRP; C-reactive protein, HR; Hazard ratio, STEMI; 
Admission index diagnosis ST-segment elevation MI, TnT; Troponin T. *Multivariable Cox regression model for comparing quartiles versus the 
lower quartileBMC Cardiovascular Disorders 2008, 8:34 http://www.biomedcentral.com/1471-2261/8/34
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patients with BNP in Q4 was 4.72 (95% CI, 1.76–12.68)
compared with Q1 (Table 4).
The hsCRP levels were significantly higher among patients
dying than in long-term survivors (6.6 (2.3–19.4) versus
3.6 (1.7–11.5) mg/L [median, 25 and 75% percentiles], p
= 0.000). However, in the multivariable Cox regression
model hsCRP rendered no prognostic information for all-
cause mortality (Table 2 &3).
Cardiac Death or Recurrent TnT Positive Cardiac Events
After a follow-up period of 24 months, 193 patients
(23.3%) had experienced a cardiac death or a recurrent
TnT positive cardiac event. Kaplan-Meier survival curves
for the secondary endpoints are presented in Figure 3.
The adjusted HR for this combined endpoint within 2
years in patients with BNP in Q4 was 2.30 (95% CI, 1.27–
4.17) compared with Q1 and was associated with the sec-
ondary endpoint above and beyond age, medical history
of diabetes mellitus, CHD and TnT concentration at
admission exceeding 0.05 ng/mL (Table 3). In addition,
in the ACS subgroup, the adjusted HR for this secondary
endpoint within 30 days and 2 years in patients with BNP
in Q4 was 4.08 (95% CI, 1.67–9.98) and 2.33 (95% CI,
1.23–4.39), respectively, compared with Q1 (Table 4).
The multivariable Cox regression model for a cardiac
death or a recurrent TnT positive cardiac event within 30
days and 2 years in patients with hsCRP in Q4 compared
with Q1 revealed no significant relation between this
biomarkers and this secondary endpoint (Table 2 &3).
Recurrent TnT Positive Cardiac Events
149 patients (18.0%) experienced a recurrent TnT positive
cardiac event after a follow-up period of 2 years. Kaplan-
Meier survival curves are presented in Figure 4.
The adjusted HR for this endpoint within 2 years in
patients with BNP in Q4 was 1.60 (95% CI, 0.81–3.18)
compared with Q1 and was not associated with a recur-
rent TnT positive cardiac event above and beyond age, HF,
medical history of MI or angina pectoris, hypertension,
diabetes mellitus and TnT values at admission (Table 3).
Within 30 days, the adjusted HR for patients with recur-
rent TnT cardiac positive events hsCRP in Q4 was 14.79
(95% CI, 1.89–115.63) compared with Q1 and was asso-
ciated with this endpoint above and beyond age, hyperc-
holesterolemia and TnT values at admission (Table 2). In
addition, in the subgroup composed of ACS patients, the
adjusted HR within 30 days in patients with hsCRP in Q4
was 12.97 (95% CI, 1.63–103.10) compared with Q1
(Table 4).
Discussion
The main findings of our study in this group of unselected
patients admitted to the ED with chest pain and potential
Table 3: Cox regression model for the total population showing association between selected baseline clinical variables and hazards 
ratios for the prespecified endpoints during 24 months follow-up
Variable Total Mortality* Cardiac Death or Recurrent TnT Positive 
Cardiac Events*
Recurrent TnT Positive Cardiac Events*
HR (95% CI) HR (95% CI) HR (95% CI)
BNP quartile 2 1.02 (0.34–3.06) 0.87 (0.47–1.64) 0.97 (0.48–1.93)
BNP quartile 3 3.52 (1.35–9.19) 1.69 (0.94–3.04) 1.51 (0.78–2.95)
BNP quartile 4 5.13 (1.97–13.38) 2.30 (1.27–4.17) 1.60 (0.81–3.18)
hsCRP quartile 2 1.00 (0.56–1.78) 1.14 (0.73–1.79) 1.64 (0.98–2.73)
hsCRP quartile 3 1.23 (0.72–2.10) 1.04 (0.66–1.62) 1.04 (0.61–1.78)
hsCRP quartile 4 0.96 (0.56–1.65) 1.28 (0.83–1.97) 1.60 (0.96–2.66)
Age 1.07 (1.04–1.09) 1.04 (1.02–1.05) 1.02 (1.01–1.04)
NYHA 3 1.78 (1.10–2.89)
STEMI 0.41 (0.24–0.67)
MI 1.68 (1.16–2.44)
Hypertension 1.67 (1.19–2.36)
NIDDM 1.54 (1.08–2.20) 1.66 (1.12–2.46)
CHF 1.57 (1.06–2.33)
TnT>0.05 (ng/mL) 2.21 (1.64–3.00) 2.52 (1.78–3.56)
Angina pectoris 1.46 (1.02–2.09)
CHD 2.09 (1.39–3.13)
BNP; B-type natriuretic peptide, CHD; Coronary heart disease, CI; Confidence interval, CHF; Congestive heart failure, CRP; C-reactive protein, 
HR; Hazard ratio, MI; Previous myocardial infarction, NIDDM; Non-insulin dependent diabetes mellitus, Non-ACS; NYHA; New-York Heart 
Association functional class, STEMI; Admission index diagnosis ST-segment elevation MI, TnT; Troponin T.
*Multivariable Cox regression model for comparing quartiles versus the lower quartileBMC Cardiovascular Disorders 2008, 8:34 http://www.biomedcentral.com/1471-2261/8/34
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Kaplan-Meier plots for the cumulative risk of cardiac death or recurrent TnT positive cardiac events for the BNP- and hsCRP  quartiles, respectively Figure 3
Kaplan-Meier plots for the cumulative risk of cardiac death or recurrent TnT positive cardiac events for the 
BNP- and hsCRP quartiles, respectively. *Log Rank (Mantel-Cox) test of equality of survival distribution for the different 
levels of the BNP and hsCRP quartiles (univariate analysis).BMC Cardiovascular Disorders 2008, 8:34 http://www.biomedcentral.com/1471-2261/8/34
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ACS, indicate that BNP is an important and independent
prognostic biomarker for both short- and long-term mor-
tality. We could not confirm the prognostic ability of
hsCRP as a predictor of mortality. However, hsCRP was
found to be a predictor of short-term recurrent TnT posi-
tive cardiac events. Furthermore, the multivariable analy-
sis showed that also some clinical variables at admission
were all independent predictors of mortality. These latter
results are in accordance with previous studies where sev-
eral clinical background factors were associated with poor
outcome [16-18]. However, after adjusting for these con-
founding factors, we found that the prognostic value of
BNP and hsCRP were still statistically significant.
Given the heterogeneous nature of ACS, patients have a
wide spectrum of risk for death and CV events. Our study
was performed in a rather inhomogeneous and unselected
patient population, but, importantly, it is similar to the
one dealt with in the ED, reflecting the setting in the clin-
ical every-day life.
In contrast to the majority of previous studies investigat-
ing the prognostic value of various biomarkers, our study
had a prospective and observational design, and blood
samples were collected directly on admission. Several
other studies have measured natriuretic peptides levels
within a few days from the onset of symptoms [4,6,20].
However, few studies have examined the predictive value
of natriuretic peptides across the spectrum of ACS in
blood samples obtained directly on admission before
introducing any kind of therapy [19]. Therefore, in the
present study we do not have to consider the potential
confounding factors of late inclusions and recently intro-
duced medical treatment; factors that need to be adjusted
for when extracting prognostic information from rand-
omized interventional studies.
Our data add to the discussion of the value of CRP as a
predictive biomarker in patients with chest pain and ACS.
Several previous studies have demonstrated an associa-
tion between elevated CRP levels and increased probabil-
ity of CHD events or death [18,21-23]. However, even if
hsCRP was not a significant predictor of survival in our
study it was shown to predict short-term recurrent TnT
positive cardiac events.
CRP has been considered for adoption into risk assess-
ment algorithms [24]. A study by Burke and colleagues
supports the concept that hsCRP in serum reflects the
numbers of vulnerable coronary atherosclerotic plaques
with superficial foam cells and large necrotic cores in
patients dying suddenly with CHD [25]. A natriuretic pep-
tide system has also been detected in human coronary
atherosclerotic plaques [26]. Interestingly, our study sug-
gests that BNP is a better risk stratification tool for survival
than CRP among patients with a potential ACS. There may
be several potential explanations for the apparently more
robust prognostic value of the natriuretic peptides, as they
integrate multiple different pathophysiological signals
within an individual, including ventricular dysfunction
[27], elevated intracardiac filling pressures [1], valvular
disease [28], ischemic burden [5] and diabetic nephropa-
thy [29]. However, the exact underlying mechanisms of
natriuretic peptides elevations in patients with ACS are
not known at present.
Recently conducted studies support our results and show
that the independent predictivity of CRP was attenuated
when it was tested in the multivariable model in the gen-
eral population [30] and together with natriuretic pep-
tides in patients with known CAD [31-33]. These
divergent findings with respect to the positive predictiv-
ity of CRP might be explained by factors such as differ-
ences in the patients' characteristics, duration of follow-
up, definitions of endpoints and by the fact that CRP is
more closely related to CV risk factors than to CV dam-
age [30].
Table 4: Cox regression model for the acute coronary syndrome subgroup showing hazard ratios for the prespecified endpoints during 
30 days and 24 months follow-up
Variable Total Mortality* Cardiac Death or Recurrent TnT 
Positive Cardiac Events*
Recurrent TnT Positive Cardiac 
Events*
HR (95% CI) HR (95% CI) HR (95% CI)
30 days 24 months 30 days 24 months 30 days 24 months
BNP quartile 2 1.01 (0.22–4.54) 2.33 (0.85–6.38) 0.98 (0.35–2.73) 1.40 (0.74–2.64) 0.42 (0.10–1.78) 1.29 (0.64–2.59)
BNP quartile 3 0.93 (0.20–4.48) 2.39 (0.88–6.54) 1.60 (0.59–4.33) 1.85 (0.99–3.48) 0.92 (0.28–3.04) 2.39 (1.24–4.61)
BNP quartile 4 3.83 (0.95–15.41) 4.72 (1.76–12.68) 4.08 (1.67–9.98) 2.33 (1.23–4.39) 1.08 (0.33–3.50) 1.88 (0.95–3.73)
hsCRP quartile 2 0.28 (0.06–1.33) 0.64 (0.33–1.21) 0.92 (0.35–2.39) 0.77 (0.46–1.27) 7.04 (0.86–57.41) 1.00 (0.57–1.76)
hsCRP quartile 3 1.98 (0.77–5.13) 1.27 (0.72–2.22) 1.78 (0.76–4.17) 0.95 (0.59–1.53) 4.02 (0.44–36.70) 0.89 (0.50–1.60)
hsCRP quartile 4 1.20 (0.45–3.18) 0.82 (0.46–1.44) 1.45 (0.61–3.42) 1.11 (0.70–1.76) 12.97 (1.63–103.10) 1.41 (0.83–2.39)
*Multivariable Cox regression model for comparing quartiles versus the lower quartileBMC Cardiovascular Disorders 2008, 8:34 http://www.biomedcentral.com/1471-2261/8/34
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Kaplan-Meier plots for the cumulative risk of recurrent TnT positive cardiac events for the BNP- and hsCRP quartiles, respec- tively Figure 4
Kaplan-Meier plots for the cumulative risk of recurrent TnT positive cardiac events for the BNP- and hsCRP 
quartiles, respectively. *Log Rank (Mantel-Cox) test of equality of survival distribution for the different levels of the BNP 
and hsCRP quartiles (univariate analysis).BMC Cardiovascular Disorders 2008, 8:34 http://www.biomedcentral.com/1471-2261/8/34
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Further studies are needed to identify therapies that may
reduce the risk associated with increased BNP or hsCRP.
We would assume that an early risk stratification of our
patient population presenting to the ED could be impor-
tant for several reasons. The finding of an early rise in the
natriuretic peptides obtained immediately after present-
ing to the ED with an ACS might be favourably influenced
by immediate or early interventions [34]. However, there
have been conflicting results regarding this topic [5]. The
observation in our study that BNP did not predict recur-
rent TnT positive cardiac events is in accordance with prior
studies [4,33]. Patients at low risk, as defined by low natri-
uretic peptides values in combination with normal tro-
ponins may benefit more from a conservative
management [34]. Thus, additional evidence regarding
optimal decision limits, use in combination with tropon-
ins and use in targeting therapy is needed before accept-
ance into clinical use for ACS.
Limitations
The potential limitations of these data merit considera-
tion. This study was conducted at a single-center, but
patients were unselected and characterized by generally
accepted diagnostic criteria, including their TnT values.
The mortality rates in the present investigation were high;
129 patients (15.6%) at 24 months, most likely due to an
unselected, consecutive recruitment, resulting in a high
percentage of elderly patients and patients with comor-
bidity. The increased long-term mortality was associated
with elevated BNP concentrations, pointing to the need
for further investigations into the underlying pathomech-
anisms of BNP release. However, we believe that these fea-
tures are common among patients with chest pain and
potential ACS and that the results are generalizable. The
circulating concentrations of BNP and CRP prior to
admission remain unknown and our analyses are based
on a single baseline determination. Although we did not
adjust for LVEF, we did adjust for known CHF and CVD,
including previous MI, and other clinical risk factors.
Conclusion
BNP may act as a clinically useful biomarker when
obtained at admission in an unselected patient popula-
tion following hospitalization with chest pain and poten-
tial ACS, and may provide complementary prognostic
information to established risk determinants at long-term
follow-up. Our data do not support the hypothesis that
the additional assessment of hsCRP will lead to better risk
stratification for survival than BNP alone.
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